145 related articles for article (PubMed ID: 22627686)
1. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?
Grasso LF; Pivonello R; Colao A
Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):288-94. PubMed ID: 22627686
[TBL] [Abstract][Full Text] [Related]
2. The effects of somatostatin analogs on biochemical parameters in acromegaly.
Liuzzi A; Marzullo P
J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of radiotherapy in acromegaly.
González B; Vargas G; Espinosa-de-los-Monteros AL; Sosa E; Mercado M
Arch Med Res; 2011 Jan; 42(1):48-52. PubMed ID: 21376263
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
5. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
6. New formulations and approaches in the medical treatment of acromegaly.
Debono M; Newell-Price J
Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant: new preparation. A last resort in acromegaly.
Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
[TBL] [Abstract][Full Text] [Related]
8. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
[TBL] [Abstract][Full Text] [Related]
9. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.
Losa M; Mortini P; Urbaz L; Ribotto P; Castrignanó T; Giovanelli M
J Neurosurg; 2006 Jun; 104(6):899-906. PubMed ID: 16776333
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
[TBL] [Abstract][Full Text] [Related]
11. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
12. Acromegaly: a review of current medical therapy and new drugs on the horizon.
Fleseriu M; Delashaw JB; Cook DM
Neurosurg Focus; 2010 Oct; 29(4):E15. PubMed ID: 20887125
[TBL] [Abstract][Full Text] [Related]
13. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogs as primary medical therapy for acromegaly.
Danoff A; Kleinberg D
Endocrine; 2003 Apr; 20(3):291-7. PubMed ID: 12721510
[TBL] [Abstract][Full Text] [Related]
15. The importance of presurgical somatostatin analogue therapy in acromegaly.
Colao A
Endokrynol Pol; 2007; 58(4):356-60. PubMed ID: 18058729
[TBL] [Abstract][Full Text] [Related]
16. Surgical-pharmacological interactions in the treatment of acromegaly.
Abreu C; Guinto G; Mercado M
Expert Rev Endocrinol Metab; 2019 Jan; 14(1):35-42. PubMed ID: 30595057
[TBL] [Abstract][Full Text] [Related]
17. Novel pathway for somatostatin analogs in patients with acromegaly.
Gadelha MR; Kasuki L; Korbonits M
Trends Endocrinol Metab; 2013 May; 24(5):238-46. PubMed ID: 23270713
[TBL] [Abstract][Full Text] [Related]
18. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.
Orlewska E; Stępień R; Orlewska K
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):15-25. PubMed ID: 30122081
[TBL] [Abstract][Full Text] [Related]
20. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
Muhammad A; van der Lely AJ; O'Connor RD; Delhanty PJ; Dal J; Dallenga AH; Feelders RA; Janssen JA; Jorgensen JO; Neggers SJ
Eur J Endocrinol; 2016 May; 174(5):663-7. PubMed ID: 26903550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
